Genotypic identification of polyclonal plasma cells in plasma cell dyscrasias shows an aberrant single-cell phenotype with clinical implications

Matteo Claudio Da Vià,Francesca Lazzaroni,Antonio Matera,Alessio Marella,Akihiro Maeda,Claudio De Magistris,Loredana Pettine,Sonia Fabris,Stefania Pioggia,Alfredo Marchetti,Marzia Barbieri,Silvia Lonati,Alessandra Cattaneo,Marta Tornese,Margherita Scopetti,Nayyer Latifinavid,Giancarlo Castellano,Federica Torricelli,Antonino Neri,Cathelijne Fokkema,Tom Cupedo,Marta Lionetti,Francesco Passamonti,Niccolò Bolli
DOI: https://doi.org/10.1101/2024.05.26.595470
2024-05-27
Abstract:Multiple Myeloma (MM) is driven by clonal plasma cell (PC)-intrinsic factors and changes in the tumorigenic microenvironment (TME). To investigate if residual polyclonal PCs (pPCs) are disrupted, single-cell (sc) RNAseq and sc B-cell receptor analysis were applied in a cohort of 46 samples with PC dyscrasias and 18 healthy donors (HDs). Out of n=213,074 CD138pos PCs, 42,717 were genotypically identified as pPCs. Compared to HDs, we detected quantitative and qualitative differences in pPCs of patients showing immunoparesis, where we showed a pro-inflammatory status, driven by specific cellular interactions with TME. Finally, we derived a "hPC signature" that, once inferred in the CoMMpass dataset, was predictive of PFS and OS. Our findings show that genotypic, single-cell identification of pPCs in PC dyscrasias has relevant pathogenic and clinical implications.
Cancer Biology
What problem does this paper attempt to address?